Despite the current lack of trials addressing the efficacy of fibrates in patients with partial lipodystrophy, our results raise concerns regarding the potential value of fibrates for the management of hypertriglyceridaemia/NAFLD in carriers of the dominant negative P467L‐PPARγ mutation. This evidence concerns the gene PPARG and partial lipodystrophy.